The effect of short-term dipyrone administration on cyclosporin pharmacokinetics

European Journal of Clinical Pharmacology

Volumn 55, Issue 6, 1999, Pages 475-478

  Caraco, Y ^a   Zylber Katz, E ^a   Fridlander, M ^a   Admon, D ^a   Levy, M ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cyclosporin; Dipyrone; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ATENOLOL; AZATHIOPRINE; CYCLOSPORIN A; DIPYRONE; MEVINOLIN; NITRAZEPAM; PLACEBO; PREDNISONE; VERAPAMIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-OVER STUDIES; CYCLOSPORINE; DIPYRONE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 0032794035     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050659     Document Type: Article

References (14)

1. Ponticelli C, Tarantino A, Montagnino G (1994) Controlled trials with cyclosporine in kidney transplantation. Transplant Proc 26: 2490-2492
2. Burke JF, Pirsch JD, Ramos EL, Salmons DR, Stablein DM, van Buren DH, West JC (1994) Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Eng J Med 331: 358-363
3. Salaman JR (1991) Renal transplantation without steroids. Pediatr Nephrol 5: 105-107
4. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871-1878
5. Combalbet J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P (1989) Metabolism of cyclosporine A: IV. purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 17: 197-217
6. Yee GC, McGuire TR (1990) Pharmacokinetic drug interactions with cyclosporin (part I). Clin Pharmacokinet 19: 319-322
7. Yee GC, McGuire TR (1990) Pharmacokinetic drug interactions with cyclosporin (part I). Clin Pharmacokinet 19: 400-415
8. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52: 453-457
9. Freeman DJ, Laupacis A, Keown PA, Striller CR, Carruthers SG (1984) Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 18: 887-893
10. Levy M, Zylber-Katz E, Rosenkranz B (1995) Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 28: 216-234
11. Geisslinger G, Bocker R, Levy M (1996) High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Pharm Res 13: 1272-1275
12. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184
13. Thummel KE, O'Shea D, Paine MF, Shen DD, Lunze KL, Perkins JD, Wikinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A4-mediated metabolism. Clin Pharmacol Ther 59: 491-502
14. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24: 475-490